Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.

By K. Petersen, E. Oral, S. Dufour, D. Befroy, C. Ariyan, Chunli Yu, G. Cline, A. DePaoli, Simeon I. Taylor, P. Gorden and 1 more. Journal of Clinical Investigation, 2002

780 citations recorded by the source corpus.

Subfields: Endocrine and Autonomic Systems, Molecular Biology, Physiology

View Paper: https://www.semanticscholar.org/paper/f904493da145e7c41e51276a4c7fac7a0460df60

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrine and Autonomic Systems

1. Gerald I. Shulman
2. E. Ravussin
3. L. Heilbronn
4. Ralph DeFronzo
5. Haiming Cao
6. P. Havel

In Molecular Biology

1. Gerald I. Shulman
2. Ralph DeFronzo
3. Haiming Cao
4. V. Samuel
5. K. Petersen
6. D. Befroy
7. S. Dufour
8. P. Havel

In Physiology

1. Gerald I. Shulman
2. Ralph DeFronzo
3. V. Samuel
4. K. Petersen
5. Haiming Cao
6. E. Ravussin
7. L. Heilbronn
8. P. Havel

Citations in the corpus

• The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. (2016, background): “Leptin therapy reduced calorie intake, resolved hepatic steatosis, and improved insulin action (63).”
• Adipocytokines in Obesity and Metabolic Disease (2014, positive): “Leptin is successfully used to treat insulin resistance and hepatic steatosis in patients with congenital severe lipodystrophy who have very low levels of circulating leptin (Oral et al. 2002, Petersen et al. 2002).”
• Insulin resistance: Review of the underlying molecular mechanisms (2018, background): “sensitivity, and reversed IR in T2D (Petersen et al., 2002).”
• Dietary fructose: implications for dysregulation of energy homeostasis and lipid/carbohydrate metabolism. (2005, background): “These effects are associated with reduced triglyceride deposition in liver and skeletal muscle.(164,165) It is now abundantly clear that leptin has a crucial role in the”
• Non Alcoholic Fatty Liver Disease, Hepatic Insulin Resistance and Type 2 Diabetes (2014, background): “Leptin is also able to correct many of the metabolic defects associated with lipodystrophy in mice and humans.(55,56) Leptin replacement in lipodystrophic patients markedly reduces both hepatic and intramyocellular lipid content, which mostly could be attributed to reduction in caloric intake, with ”
• Calorie restriction and aging: review of the literature and implications for studies in humans. (2003, background): “In subjects with congenital acquired lipodystrophy (the absence of fat and leptin), the administration of exogenous recombinant leptin normalizes the metabolic milieu (152, 153).”
• Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. (2004, background): “Replacement therapy with leptin mobilizes fat out of the liver and muscle, leading to dramatic improvements in hepatic and muscle sensitivity to insulin and improved glycemic control (239, 240).”